Shots:

• The vaccines composing the two-dose regimen- Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) receives EC’s approval under exceptional circumstances- following accelerated assessment of the MAAs and CHMP’s positive opinion
• The regimen includes Ad26.ZEBOV as the first dose- based on Janssen’s AdVac viral vector technology- and MVA-BN-Filo as the second dose- based on Bavarian Nordic’s MVA-BN technology- administered ~8wks. later
• Janssen’s vaccine regimen is indicated for active immunization to prevent Ebola virus disease caused by the Zaire ebolavirus species in individuals aged ≥1yrs.

Click here to read full press release/ article 

Ref: PRNewswire | Image: Janssen